Spain Flu Diagnostic and Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

The Spain flu diagnostic and treatment market is projected to grow at a CAGR of 9.71% throughout the forecast period to reach US$1,432.649 million in 2027, from US$749.058 million in 2020.

The flu diagnostic and treatment market in Spain is anticipated to grow throughout the forecast period on account of the increasing government focus on the improvement of access to healthcare services among the population of the country. Furthermore, the rising healthcare expenditure, primarily for the adoption of technology for the improvement of the country’s healthcare infrastructure, is also expected to propel the market’s growth at a decent rate throughout the forecast period and beyond. As this trend continues, and accessibility to healthcare services improves among people, opportunities for market players to generate higher revenues are increasing. Spain is considered one of the fastest-growing economies in the European Union. It is the 14th largest economy in the world, and even after years of recession in the economy, the country marked the third straight year of at least 3% GDP growth. The pharmaceutical industry of the country is also gaining a lot of attraction as the country’s pharma sector is developed into one of the top players across the European region.

The Spanish flu diagnostic and treatment market is expected to grow due to a good public healthcare system, the rising prevalence of flu, seasonal flu, and others.

The country’s public healthcare system further gives numerous advantages to the pharmaceutical industry as there are growing investment commitments in the market. All these factors are collectively supporting the flu diagnostic and treatment market in the country. Furthermore, the rising prevalence of flu throughout the country is leading to an increasing number of hospitalizations along with a surge in the number of doctor visits, which is anticipated to positively impact the market growth during the forecast period and beyond. In addition, the high number of primary care cases due to the outbreak of seasonal flu is also fueling the number of hospitalizations and treatment procedures in the country, which is also bolstering the market growth for the coming years. Furthermore, the presence of state-of-art healthcare in the country is also supplementing the flu diagnostic and treatment market growth in the coming years.

Product Offerings

• F. Hoffmann-La Roche Ltd. provides the Cobas® SARS-CoV- 2 and Influenza A & B tests. The company claims that the test kit can differentiate between COVID-19 and Flu. The test only takes 20 mins with minimum cross-contamination and risk of exposure during testing with the closed-system design.
• Abbott’s ID NOWTM INFLUENZA A&B 2 molecular test is available in Argentina, it delivers the results in 13 minutes or less by means of unique ID NOW platforms. Thus, making the test much faster and more accurate than other influenza tests. It detects up to 42% more true positives than RADTs.
• VIASURE real-time PCR detection kits are produced by CerTest Biotec. The kit offers a real-time RT-PDR test designed for the detection of RNA from the influenza flu A&B and SARS-CoV-2. The test offered by CerTest Biotec, a Spanish biotech co, which extracts RNA from respiratory specimens, the n using RT-PCR RNA is amplified and detected using fluorescent reporter dye probes for Flu A&B and SARS-CoV2.

COVID-19 Insight

During COVID-19, the different hygiene and physical distancing measures have played a vital role in reducing influenza virus transmission. The Spanish flu was under control during this period owing to the efforts of the Spanish government to contain the spread of COVID-19. Although with the gradual release of the pandemic restrictions and protocols, the case of Spanish flu has increased in the country. Hence, the Spanish flu diagnostics and treatment market is expected to grow during the forecast period.

Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory

Abbott

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc.

3M

Meridian Bioscience™

CerTest Biotec S.L.